ChemBriefCyclic Peptides Gain Momentum in Drug Development
Merck's cyclic peptide enlicitide secured an FDA priority voucher, aiming to become the first oral PCSK9 inhibitor. Forecasts exceed $2 billion in annual sales, underscoring a rising trend in peptide-
cen · 2026-06-01 00:00 UTC